Founded in July 2001, Chengdu Shengnuo Biotechnology Co., Ltd. has advanced and efficient peptide drug technology R & D and large-scale production capacity.
Founded in July 2001, Chengdu Shengnuo Biotechnology Co., Ltd. is a high-tech enterprise with core technology of peptide synthesis and modification, with advanced and efficient peptide drug process R & D and large-scale production capacity. On June 3, 2021, the company was listed on the science and Innovation Board of Shanghai Stock Exchange.
Based on cdmo business and relying on its technical advantages in peptide drug R & D and large-scale production, the company provides pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and technology transfer services for peptide drug production for pharmaceutical enterprises at home and abroad.
The company has now established a whole process R & D pipeline and a whole industry chain platform including GMP grade API and preparation production lines, and has mastered rich core technology and industrialization experience. The company independently develops, produces and sells peptide API and preparation products with large market capacity and strong competitiveness at home and abroad, It has successfully developed 15 varieties of polypeptide APIs and 9 varieties of preparations, obtained nearly 30 production approvals or records at home and abroad, and has become one of the most powerful polypeptide R & D and production enterprises in China.